Finerenone demonstrated significant renal protection in Asian patients with type 2 diabetes and chronic kidney disease. A pooled subanalysis from the FIDELITY program, published in the Journal of Diabetes and Its Complications, confirmed that finerenone slowed kidney function decline and reduced albuminuria compared with placebo.

Among 2,858 Asian participants, finerenone improved chronic eGFR slope by a least-squares mean difference of 1.08 mL/min/1.73 m² compared with placebo (95% CI: 0.53–1.63; p = 0.0002). The treatment lowered urine albumin-to-creatinine ratio (UACR) by 34% from baseline to month 4, independent of baseline kidney function, blood pressure, or concurrent SGLT2 inhibitor or GLP-1 receptor agonist use.

Albuminuria regression to normal levels occurred in 39.5% of patients receiving finerenone compared with 14.8% of those on placebo. Adverse events were similar between groups, and hyperkalemia was generally mild and manageable.

These findings support finerenone as an effective option for preserving kidney function and reducing albuminuria in Asian patients with type 2 diabetes and chronic kidney disease.